E3-Hormone Refractory Prostrate Cancer Taxotere Combination

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

September 30, 2008

Conditions
Prostate CancerMetastaticHormone Refractory
Interventions
DRUG

Zactima (vandetanib)

DRUG

Docetaxel

DRUG

Prednisolone

Trial Locations (11)

Unknown

Research site, Rio de Janeiro

Research Site, São Paulo

Research Site, Hamburg

Research Site, Hanover

Research Site, Kassel

Research Site, Tübingen

Research Site, Budapest

Research Site, Bloemfontein

Research Site, Cape Town

Research Site, Umeå

Research Site, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Sanofi

INDUSTRY

NCT00498797 - E3-Hormone Refractory Prostrate Cancer Taxotere Combination | Biotech Hunter | Biotech Hunter